PortalPublikationenTherapeutic potential and limitations of new FAK inhibitors ...

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.

Standard

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. / Schultze, Alexander; Fiedler, Walter.

in: EXPERT OPIN INV DRUG, Jahrgang 19, Nr. 6, 6, 2010, S. 777-788.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schultze, A & Fiedler, W 2010, 'Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.', EXPERT OPIN INV DRUG, Jg. 19, Nr. 6, 6, S. 777-788. <http://www.ncbi.nlm.nih.gov/pubmed/20465362?dopt=Citation>

APA

Schultze, A., & Fiedler, W. (2010). Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. EXPERT OPIN INV DRUG, 19(6), 777-788. [6]. http://www.ncbi.nlm.nih.gov/pubmed/20465362?dopt=Citation

Vancouver

Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. EXPERT OPIN INV DRUG. 2010;19(6):777-788. 6.

Bibtex

@article{8bc6e816895b49909de2701520984e7d,
title = "Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.",
abstract = "Activation of the non-receptor tyrosine kinase focal adhesion kinase (FAK) has been implicated in progression of multiple mesenchymal and epithelial malignant tumors. FAK plays an important role in regulation of proliferation, migration and apoptosis of neoplastic cells.",
author = "Alexander Schultze and Walter Fiedler",
year = "2010",
language = "Deutsch",
volume = "19",
pages = "777--788",
journal = "EXPERT OPIN INV DRUG",
issn = "1354-3784",
publisher = "informa healthcare",
number = "6",

}

RIS

TY - JOUR

T1 - Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.

AU - Schultze, Alexander

AU - Fiedler, Walter

PY - 2010

Y1 - 2010

N2 - Activation of the non-receptor tyrosine kinase focal adhesion kinase (FAK) has been implicated in progression of multiple mesenchymal and epithelial malignant tumors. FAK plays an important role in regulation of proliferation, migration and apoptosis of neoplastic cells.

AB - Activation of the non-receptor tyrosine kinase focal adhesion kinase (FAK) has been implicated in progression of multiple mesenchymal and epithelial malignant tumors. FAK plays an important role in regulation of proliferation, migration and apoptosis of neoplastic cells.

M3 - SCORING: Zeitschriftenaufsatz

VL - 19

SP - 777

EP - 788

JO - EXPERT OPIN INV DRUG

JF - EXPERT OPIN INV DRUG

SN - 1354-3784

IS - 6

M1 - 6

ER -